Market closed
Unicycive Therapeutics/$UNCY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Unicycive Therapeutics
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
Ticker
$UNCY
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
14
Website
UNCY Metrics
BasicAdvanced
$62M
-
-$0.56
2.15
-
Price and volume
Market cap
$62M
Beta
2.15
52-week high
$0.69
52-week low
$0.45
Financial strength
Current ratio
1.283
Quick ratio
1.084
Long term debt to equity
1.574
Total debt to equity
9.164
Interest coverage (TTM)
-452.35%
Management effectiveness
Return on assets (TTM)
-87.54%
Return on equity (TTM)
-2,028.11%
Valuation
Price to book
7.9
Price to tangible book (TTM)
7.9
Price to free cash flow (TTM)
-1.206
Growth
Earnings per share change (TTM)
-55.89%
3-year earnings per share growth (CAGR)
-13.01%
UNCY News
AllArticlesVideos
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewsWire·5 days ago
Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update
GlobeNewsWire·6 days ago
Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Unicycive Therapeutics stock?
Unicycive Therapeutics (UNCY) has a market cap of $62M as of April 06, 2025.
What is the P/E ratio for Unicycive Therapeutics stock?
The price to earnings (P/E) ratio for Unicycive Therapeutics (UNCY) stock is 0 as of April 06, 2025.
Does Unicycive Therapeutics stock pay dividends?
No, Unicycive Therapeutics (UNCY) stock does not pay dividends to its shareholders as of April 06, 2025.
When is the next Unicycive Therapeutics dividend payment date?
Unicycive Therapeutics (UNCY) stock does not pay dividends to its shareholders.
What is the beta indicator for Unicycive Therapeutics?
Unicycive Therapeutics (UNCY) has a beta rating of 2.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.